Zomig (Zolmitriptan): Authoritative Regulatory & Pharmaceutical Data Summary

International Nonproprietary Name (INN): Zolmitriptan[1]

Brand Names and Packaging (Global)

ATC Code: N02CC03 (Serotonin (5-HT_1B/1D) agonists, selective – Antimigraine preparations)[1]

Forms & Dosages

• Zomig Tablets: 1.25 mg, 2.5 mg, 5 mg (oral, swallow whole or disintegrating)[2][3]
• Zomig-ZMT: Orally disintegrating tablets (lactose-free, 2.5 mg, 5 mg)
• Zomig Nasal Spray: 5 mg in single-use device

Manufacturers & Suppliers

Global Marketing Authorization Holder (MAH): AstraZeneca (original sponsor)[1]

Local Manufacturers/MAHs: Varies by country; in the US and EU, generics are available from multiple pharmaceutical firms under the INN “zolmitriptan.”

Worldwide Suppliers: Major global and regional pharma distributors stock Zomig and generics; e-pharmacies carry both brands and generics, often with country-specific packaging (blisters, boxes, patient leaflets in local language).

Registration & Approval Status

FDA Approval: Initial US approval in 1997[1][3].

EMA Approval: Approved in the EU for acute migraine treatment.

ANMDMR (Romania): Zomig is registered with the National Agency for Medicines and Medical Devices (ANMDMR) and is available by prescription; exact regulatory documents can be found on the ANMDMR online database.

Other Markets: Registered in Japan (PMDA), Canada (Health Canada), Australia (TGA), and others.

Classification

Rx only – Prescription required in all major markets[2][3]. Not available OTC.

Standard Dosages per Condition

Acute Migraine (with or without aura): Recommended starting dose 1.25 mg or 2.5 mg; maximum single dose 5 mg; may repeat after 2 hours if needed, not to exceed 10 mg in 24 hours[3]. Use only after clear diagnosis of migraine[3]. Not indicated for migraine prophylaxis or cluster headache[2][3].

Dosage Adjustments

• Children: Not approved in children; safety and efficacy not established.
• Elderly: Caution advised; consider lower doses due to potential for reduced hepatic function.
• Liver Impairment: Dose adjustment may be necessary; consult prescribing information.
• Kidney Impairment: No specific adjustment stated in labeling.

Typical Treatment Duration & Regimen

Treatment is symptomatic; use at the onset of migraine attack. Not for chronic or preventive use. Patient may take a second dose if headache returns after 2 hours, but must not exceed maximum daily dose[3].

Missed Dose, Overdose, Storage, & Transport

• Missed Dose: Not applicable—take at onset of symptoms; no scheduled dosing.
• Overdose: Symptoms may include sedation, hypertension, cardiovascular events. Standard supportive care required.
• Storage: Store at room temperature (15–30°C), protect from light and moisture. Nasal spray: do not refrigerate or freeze.
• Transport: Standard pharmaceutical precautions; avoid temperature extremes.

Absolute Contraindications

• Ischemic heart disease (angina, history of MI)
• Coronary artery vasospasm (Prinzmetal’s angina)
• Uncontrolled hypertension
• History of cerebrovascular events (stroke, TIA)
• Peripheral vascular disease
• Severe hepatic impairment
• Hypersensitivity to zolmitriptan or any component

Relative Contraindications (Use with Caution/Monitoring)

• Controlled hypertension
• Mild to moderate hepatic impairment
• Patients at risk for unrecognized coronary artery disease (e.g., postmenopausal women, males >40 years)
• Pregnancy (Category C; only if benefit justifies risk)
• Breastfeeding

Common Side Effects (Mild to Moderate)

• Dizziness
• Nausea
• Somnolence
• Paresthesia
• Chest discomfort
• Dry mouth
• Fatigue
• Weakness
• Throat/neck pain or tightness

Competitors and Word-Use Cases

Direct Competitors (other triptans): Sumatriptan (Imitrex, Imigran), Rizatriptan (Maxalt), Eletriptan (Relpax), Almotriptan (Axert), Naratriptan (Amerge), Frovatriptan (Frova)[1].

Word-Use Cases for SEO/Pharmacy Searches: “migraine relief fast,” “acute migraine tablet,” “zolmitriptan buy online,” “Zomig vs sumatriptan,” “Zomig nasal spray,” “migraine treatment without aura,” “Zomig-ZMT ODT,” “Zomig prescription online,” “serotonin agonist migraine.”

Additional Regulatory & Practical Notes

• Drug Interactions: Use with caution with MAO inhibitors, cimetidine (dose adjustment required), and other serotonergic drugs (risk of serotonin syndrome)[3].
• Monitoring: Regular cardiovascular assessment advised in patients with risk factors.
• Patient Counseling: Emphasize that Zomig is not a general pain reliever and should not be used for non-migraine headaches[2].
• Market Positioning: Zomig is positioned as a second-generation triptan, with improved oral bioavailability and lipophilicity compared to sumatriptan, but similar efficacy and safety profile[1].

  For the most current public regulatory data (including ANMDMR or other national agencies), always consult the official drug database or product leaflet provided with the medication in your region.